Integene International
2010
FOUNDED
OOB
STATUS
Out of Business
LATEST DEAL TYPE
Description
Developer of a platform technology for treatments of vascular diseases. The company develops a technology for the treatment of cardiovascular ischemic disease using combinations of gene and stem cell procedures.
Website
Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 1951 North West 7th Avenue
- Suite 300
- Miami, FL 33136
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Integene International’s full profile, request a free trial.
Integene International Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 01-Oct-2017 | 00000 | Completed | Out of Business | ||
| 3. Accelerator/Incubator | 13-Aug-2014 | 00000 | 00000 | Completed | Startup | |
| 2. Angel (individual) | Completed | Startup | ||||
| 1. Grant | $10M | Completed | Startup |
Integene International Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Jimmy DeMesa MD | Chief Executive Officer | ||
| Keith Webster Ph.D | Founder & Chief Scientific Officer | ||
| Michael Gold | Vice President & Executive Chairman |
Integene International Board Members (3)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Eduardo De Marchenna MD | Integene International | Board Member | 000 0000 | |
| Marvin Sackner MD | Integene International | Board Member | 000 0000 | |
| Michael Gold | Integene International | Vice President & Executive Chairman | 000 0000 |